Hydrogen-bonded organic framework-based bioorthogonal catalysis prevents drug metabolic inactivation

Congcong Huang,Chuanqi Zhao,Qingqing Deng,Haochen Zhang,Dongqin Yu,Jinsong Ren,Xiaogang Qu
DOI: https://doi.org/10.1038/s41929-023-00999-0
IF: 37.8
2023-08-11
Nature Catalysis
Abstract:Bioorthogonal chemistry provides a new avenue for disease treatment by generating therapeutic agents in situ. However, two crucial issues have to be considered for future practical applications. One is the prevention of metabolic inactivation of the in situ-synthesized drug molecules. The other is enhancing the biocompatibility and tumour cell selectivity of the bioorthogonal catalyst. Here, to tackle the above issues, we design a biocompatible hydrogen-bonded organic framework-based dual prodrugs activation platform (namely Apt@E-F@PHOF-1). The ferric porphyrin ligands of hydrogen-bonded organic framework-based bioorthogonal pre-catalyst are reduced to ferrous porphyrin by the abundant glutathione in tumour, which then catalyses the cleavage reaction to synthesize 5-fluorouracil (5FU) and 5-ethynyluracil. The 5FU catabolic enzyme inhibitor 5-ethynyluracil prevents 5FU metabolic inactivation. As an example of hydrogen-bonded organic framework-based bioorthogonal prodrug activation, this work provides insights into prevention of drug inactivation by using bioorthogonal chemistry, thus enhancing tumour inhibition and reducing therapeutic side effects demonstrated by both in vitro and orthotopic metastatic mouse model experiments.
chemistry, physical
What problem does this paper attempt to address?
The paper aims to address two key issues of bioorthogonal chemistry in disease treatment: 1. **Preventing Drug Metabolism Inactivation**: Many drug molecules synthesized in situ within cells are easily inactivated by enzyme-mediated metabolic processes, leading to poor clinical efficacy. For example, 5-fluorouracil (5FU) is metabolized by dihydropyrimidine dehydrogenase (DPD) into an inactive form. 2. **Enhancing Biocompatibility and Tumor Cell Selectivity**: Existing bioorthogonal catalysts (such as transition metal catalysts) often have poor biocompatibility and selectivity, limiting their application in biomedicine. To address these issues, researchers designed a dual prodrug activation platform based on hydrogen-bonded organic frameworks (HOF) (Apt@E-F@PHOF-1). This platform utilizes the high concentration of glutathione (GSH) in the tumor microenvironment to reduce iron porphyrin ligands to ferrous porphyrin, thereby catalyzing the generation of 5-fluorouracil (5FU) and 5-ethynyluracil (5EU). 5EU acts as a 5FU metabolism inactivation inhibitor, preventing 5FU from being inactivated by the DPD enzyme. Experimental results show that this strategy can effectively improve tumor inhibition effects and reduce treatment side effects.